Polycythemia vera (PV), essential thrombocythemia (ET), and myeloid metaplasia with myelofibrosis (MMM) are clonal disorders arising from hematopoietic progenitors. An internet-based protocol was used to collect clinical information and biological specimens from patients with these diseases. High-throughput DNA resequencing identified a recurrent somatic missense mutation JAK2V617F in granulocyte DNA samples of 121 of 164 PV patients, of which 41 had homozygous and 80 had heterozygous mutations. Molecular and cytogenetic analyses demonstrated that homozygous mutations were due to duplication of the mutant allele. JAK2V617F was also identified in granulocyte DNA samples from 37 of 115 ET and 16 of 46 MMM patients, but was not observed in 269 normal individuals. In vitro analysis demonstrated that JAK2V617F is a constitutively active tyrosine kinase.
Introduction
are caused by acquired somatic mutation in hematopoietic progenitors, but the genetic basis has not been known (Adam-Myeloproliferative disorders (MPD) include polycythemia vera son et al., 1976; Gilliland et al., 1991) . Reports of decreased (PV), essential thrombocythemia (ET), myeloid metaplasia with expression of the thrombopoietin receptor in platelets from pamyelofibrosis (MMM), chronic myelogenous leukemia (CML), tients with PV, and of overexpression of the antiapoptotic prochronic myelomonocytic leukemia (CMML), hypereosinophilic tein Bcl-x in PV (Moliterno et al., 1998; Silva et al., 1998) , suggest that abnormalities in signal transduction and in apoptosis syndrome (HES) , and systemic mast cell disease (SMCD). A clonal population of hematopoetic cells has been observed in are important in the pathogenesis of PV and other MPD. In addition, activating mutations in the erythropoietin (EPO) re-patients with PV, ET, and MMM, indicating that these diseases ceptor and in the von Hippel-Lindau (VHL) protein have been lovics et al., 1997; Pastore et al., 2003; Sokol et al., 1995) .
Median age, years (range) 59 In contrast to PV, ET, and MMM, the molecular pathogenesis Median age at diagnosis, years (range) 52 of several other MPD has been well characterized, and is fre-Race, n (%) Caucasian 325 (94) quently attributable to mutations that result in constitutive acti-Hispanic 10 (2.9) vation of a protein tyrosine kinase. Furthermore, these mutant Asian 4 (1.2) kinases have proven to be good candidates for molecularly Black/African-American 1 (0.3) targeted therapy. The paradigm established by Druker and col-Multiracial or other 5 (1.5) Self-reported diagnosis, n (%) leagues is the BCR-ABL gene rearrangement associated with PV 171 (50) CML (Bartram et al., 1983) , which is effectively treated with ET 126 (37) the small molecule tyrosine kinase inhibitor imatinib (Gleevec) MMM 46 (13) (Druker et al., 2001) . In addition to ABL, imatinib also inhibits MPD, NOS 2 (0.6) PDGFR family members, which has led to the successful treat-Median disease duration, months (range) Case series 68 ment of patients with PDGFRB rearrangements and CMML PV 60 (4-433) (Golub et al., 1994) and patients with the FIP1L1-PDGFRA fu- sion and HES (Cools et al., 2003) . Other examples of mutant tyrosine kinases in MPD include FGFR1 gene rearrangements
Prior thrombosis, n (%) Case series 76 (22) in stem cell myeloproliferative disorders (Xiao et al., 1998), and PV 31 (18) activating mutations in KIT in systemic mast cell disease itsu et al., 1993) . Thus, tyrosine kinases are often mutated in MMM 5 (11) MPD, and have been demonstrated to be excellent targets for PV, polycythemia vera; ET, essential thrombocythemia; MMM, myeloid metaplasia therapeutic intervention.
with myelofibrosis.
These observations suggest the hypothesis that activating mutations in tyrosine kinases are important in the pathogenesis of PV, ET, and MMM. We used an internet-based clinical protocol and high-throughput DNA sequence analysis to screen for JAK2 mutations in myeloproliferative disorders tyrosine kinase mutations in PV, ET, and MMM. 93 granulocyte DNA samples from PV patients were initially evaluated for sequence alterations in the activation loops and Results known autoinhibitory domains of 85 tyrosine kinases, and we identified a recurrent guanine to thymine substitution in JAK2 Myeloproliferative disorders study exon 14 that results in a valine to phenylalanine substitution at 586 patients expressed interest in the study, and 345 particicodon 617 within the JH2 autoinhibitory domain (Figures 1Apants consented to participate and returned the questionnaire 1C). Sequence analysis of the entire open reading frame of and at least one biologic sample (Supplemental Figure S1 ). The JAK2 in these 93 PV patients identified novel germline nonsynclinical characteristics of the 345 participants are shown in Taonymous substitutions (R1063H in 3 patients, R340Q in 1 pable 1. The median age of the case series was 59 (range 31-84 tient, R564L in one patient), but we did not identify additional years) and the median age at diagnosis was 52 (range 17-78 somatic mutations in JAK2. We did not identify somatic mutayears). The majority of patients were female (59%), and the tions in the other tyrosine kinases analyzed. We subsequently majority of patients were Caucasian (94%). By patient selfsequenced exon 14 of JAK2 in all patients in the case series report, the cross-sectional study included 171 patients with PV with self-reported PV, ET, and MMM ( Table 2) . Analysis of gran-(50%), 126 patients with ET (37%), and 46 patients with MMM ulocyte DNA from 164 PV patients identified heterozygous (13%). 2 patients did not provide a specific diagnosis and were JAK2V617F mutations in 80 (49%) patients and homozygous classified as MPD "not otherwise specified." The internet remutations in 41 (25%) patients. Of 115 patients with ET, 34 cruitment method selected for a highly educated and affluent (30%) were heterozygous and 3 (3%) were homozygous for the population; 60% of participants were college graduates, and JAK2V617F allele. Of 46 patients with MMM 12 (26%) were 47% reported incomes greater than $75,000/year. All patients provided blood samples, and 338 patients provided buccal heterozygous and 4 (9%) were homozygous for the JAK2V617F swabs. Of 345 blood samples, 327 (95%) yielded sufficient allele. Sequence analysis of cDNA from selected PV patients DNA for sequence analysis. We retrospectively abstracted confirmed expression of both mutant and wild-type alleles in medical records to verify patient self-reported diagnoses. Medheterozygous patients. ical records were available for 304 patients, and we were able to verify self-reported diagnosis for 249/257 (97%) patients Analysis of DNA derived from buccal mucosa Buccal swabs were provided by 338 patients, and 313 buccal who provided sufficient medical records (Supplemental Data, section "MPD patients with confirmed diagnoses"). These re-DNA samples were evaluable for the JAK2V617F mutation. 301/313 (96%) buccal DNA samples did not contain the sults demonstrate the feasibility of using the internet to recruit and enroll patients in a clinical protocol, and that patient self-JAK2V617F allele, but heterozygous JAK2V617F alleles were identified in buccal DNA samples from 11 patients with PV and report correlates with confirmed diagnosis by medical record abstraction.
one patient with MMM. In 7 cases, PV patients had a heterozy- HapMap Consortium, 2003) . The samples were locus ( Figure 1C ). In the remaining cases, buccal and granulocollected from four populations: CEPH (Centre d'Etude du cyte DNA were heterozygous. The JAK2V617F allele was not Polymorphism Humain)-Utah residents with Caucasian anidentified in buccal DNA from any patients with ET. These data cestry from Northern and Western Europe (30 parent-offspring indicate the JAK2V617F is an acquired somatic mutation in the trios, or 120 independent chromosomes); Yoruba, Nigeria (30 majority of patients with MPD. parent-offspring trios, or 120 independent chromosomes); Han V617F genotyping in the general population Chinese (45 unrelated individuals, or 90 independent chromo-To assess the prevalence of the V617F allele in normal individsomes); and Japanese (45 unrelated individuals, or 90 independent chromosomes). Pilot matrix-assisted laser desorption/ uals of Caucasian descent, and in the general population, we ionization time-of-flight mass spectrometry (MALDI-TOF MS) uals in the CEPH panel, the difference was significant (p = 0.021 by Fisher's exact test). genotyping of 95 granulocyte and buccal DNA samples from our case series correctly identified all JAK2V617F alleles identified by conventional DNA sequencing. High-confidence geno-Loss of heterozygosity at the JAK2 locus is due to mitotic recombination types were obtained using the MALDI-TOF MS assay for 269 of the 270 HapMap samples (Figure 2A ). All 269 samples were
We amplified and sequenced a synonymous single nucleotide polymorphism in JAK2 exon 6 (refSNP ID: rs2230722) 22.8 kb homozygous for the wild-type V617 allele. Comparing the frequency of the JAK2V617F allele in buccal DNA from patients upstream of JAK2V617F in buccal DNA from 17 patients with homozygous JAK2V617F mutations. Seven patients were het-with PV, 94% of whom are Caucasian, with unaffected individ- C: Quantitative PCR for the JAK2 locus relative to Factor VIII for 4 patients, each with wild-type JAK2 (green), heterozygous JAK2V617F mutations (blue), or homozygous JAK2V617F mutations (yellow). Error bars denote the standard deviation for each sample measured in triplicate. All samples tested showed two copies of the JAK2 locus, consistent with mitotic recombination in homozygotes. D: FISH analysis of one patient with a known homozygous JAK2V617F mutation with probes upstream (red) and downstream (green) of the JAK2V617F mutation, demonstrating two copies of the JAK2 locus, also consistent with mitotic recombination.
erozygous for the polymorphism in their buccal DNA, and all 7 line ( Figure 4A ), but not in K562, MOLT16, or RPMI-8402 cell lines. JAK2V617F was constitutively tyrosine-phosphory-demonstrated loss of heterozygosity in their granulocyte DNA ( Figure 2B ). To distinguish between deletion of the wild-type lated in HEL cells, as were downstream effectors STAT5 and ERK ( Figure 4B ). Furthermore, treatment with a small molecule allele and mitotic recombination, we performed quantitative genomic polymerase chain reaction (PCR) on 32 granulocyte inhibitor of JAK2 (Thompson et al., 2002) showed a dosedependent inhibition of proliferation of HEL cells, but not leuke-DNA samples, including 16 samples from patients with homozygous JAK2V617F mutations ( Figure 2C ). In all cases ana-mia cell lines K562 ( Figure 4C ), MOLT16, or RPMI-8402 (data not shown). Inhibition of proliferation corresponded with re-lyzed there were two copies of the JAK2 locus, consistent with reduplication of the mutant allele. Fluorescent in situ hybridiza-duced phosphorylation of JAK2 and STAT5 ( Figure 4D ). Moreover, treatment of HEL cells with the JAK2 inhibitor resulted in tion (FISH) analysis confirmed the presence of two copies of the JAK2 locus in 35 patients, including in 12 patients with induction of apoptosis, which was not observed in the control cell line K562 that is known to express the constitutively active homozygous JAK2V617F mutations ( Figure 2D ). tyrosine kinase BCR-ABL ( Figure 4E ). These findings indicate that JAK2V617F is a constitutively activated tyrosine kinase Comparison of genotype and clinical outcome Considering the case series as a whole, no association was that enhances hematopoietic cell proliferation and survival, and is sensitive to inhibition with small molecule inhibitors. observed between mutational status and current age, age at diagnosis, gender, race, comorbidity, physical functioning, prior thrombosis, or self-reported family history (data not Discussion shown). However, subjects with PV were more likely to have a detectable mutation in their granulocyte DNA (74% versus
We identified JAK2V617F mutations in granulocyte DNA from 3/4 of PV patients, as well as in a substantial fraction of ET 33%, p < 0.0001) or buccal DNA (7% versus 1%, p = 0.003) than subjects with either ET or MMM. In addition, within the and MMM patients. Sequence analysis showed wild-type JAK2 sequence in DNA from buccal mucosa of 301/313 (96%) PV subset, women were more likely than men to have either a heterozygous or homozygous mutation (83% versus 64%, p = evaluable patients, providing strong genetic evidence that JAK2V617F is an acquired somatic disease allele that arises 0.004). A homozygous mutation was associated with a longer duration of disease than either heterozygous or no mutation in hematopoietic progenitors and confers a selective growth advantage. In addition, a significant proportion of patients had among patients with PV or ET (median 89 versus 61 months, p = 0.008), but not MMM. No association was seen between homozygous mutations due to mitotic recombination, as has been described in patients with homozygous FLT3 mutations the presence of the JAK2V617F allele in buccal DNA and selfreported family history of MPD.
with retention of two copies of the FLT3 locus (Frohling et al., 2002) . Since JAK2V617F is an acquired mutation, duplication of the mutant allele is most likely due to mitotic recombination.
Structural and functional analysis of JAK2V617F
The JH2 (pseudokinase) domain lacks several residues that are This provides genetic evidence that JAK2V617F confers a further selective advantage when two mutant alleles of JAK2 are critical for phosphotransferase activity, but is expected to adopt the overall protein architecture that is characteristic of present.
The JAK2V617F mutation constitutively activates the JAK2 bona fide tyrosine and serine/threonine kinases. Using the SwissModel automated comparative protein modeling server, tyrosine kinase as assessed by anti-phosphotyrosine blotting. The increase in phosphotyrosine content cannot be explained we constructed a homology model of the JAK2 JH2 domain using the structure of Bruton's tyrosine kinase (Mao et al., as a consequence of overexpression alone, in that wild-type JAK2 is not tyrosine-phosphorylated when expressed at com-2001) (PDB accession code 1K2P), which has a 26% identity to the JAK2 JH2 domain. Val617 is expected to lie on the upper parable levels. Selection for cells with homozygous JAK2V617F alleles suggests either that the native JAK2 has dominant in-surface of the N-terminal lobe of the JH2 domain, at the C-terminal end of strand β4 ( Figure 3A ). Modeling suggests terfering activity for the mutant JAK2V617F, or that duplication of the allele confers a selective advantage compared to cells that this residue is largely solvent-exposed, and that substitution with phenylalanine is unlikely to significantly destabilize the with only one mutant allele. The observation that expression of increasing levels of wild-type JAK2 has no effect on phospho-fold of the domain. This residue is a component of a surface patch that is conserved among JAK pseudokinase domains.
tyrosine content of JAKV617F in 293T cells favors the latter hypothesis, but should also be evaluated in hematopoietic In functional assays, JAK2V617F, but not wild-type JAK2, was a constitutively activated tyrosine kinase as assessed by contexts in which the erythropoietin receptor (EPOR) is expressed as well. autophosphorylation ( Figure 3B ) when expressed in 293T cells. When increasing amounts of wild-type JAK2 were coexpressed JAK2V617F, but not JAK2, confers factor-independent growth to Ba/F3 cells stably transduced with the EPOR, as well as with JAK2V617F, there was no change in the level of JAKV617F tyrosine phosphorylation ( Figure 3C ), suggesting that the wild-hypersensitivity to erythropoietin. These data are in consonance with observations in PV patients in which erythropoietin-type allele does not interfere with constitutive activation of JAK2V617F. Expression of JAK2V617F, but not wild-type JAK2, independent BFU-E may be generated, and which show hypersensitivity to erythropoietin (Prchal and Axelrad, 1974; Zanjani in Ba/F3-EPOR cells conferred erythropoietin hypersensitivity and erythropoietin-independent survival, consistent with in vi-et al., 1977) . In addition, we report that the HEL cell line contains a homozygous JAK2V617F mutation. HEL cells, but not tro erythroid colony formation in patients with PV ( Figure 3D ) (Prchal and Axelrad, 1974; Zanjani et al., 1977) . cells with wild-type JAK2, undergo apoptotic cell death in response to a JAK inhibitor. Furthermore, activity of JAK2V617F Sequence analysis of the HEL human erythroleukemia cell line identified a homozygous JAK2V617F mutation in this cell and the downstream effector STAT5, as assessed by phospho-tyrosine content, are also inhibited. These data collectively indicate that JAK2V617F is a gain-of-function allele that results in expression of a constitutively activated tyrosine kinase that confers predicted growth properties to hematopoietic cells, and is sensitive to small molecule inhibition. The mechanism of activation of JAK2 by the V617F substitution is not known, but the JH2 pseudokinase domain is thought to inhibit the activity of the JAK2 kinase (JH1) domain, in that deletion of the JH2 domain leads to a marked increase in JAK2 kinase activity (Saharinen et al., 2000) . Autoinhibition of receptor tyrosine kinases is often accomplished by residues within the kinase domain or by immediately adjacent juxtamembrane or C-terminal sequences, with activating mutations in these regions identified in Kit, Flt-3, and EGFR (Furitsu et al., 1993; Lynch et al., 2004; Nakao et al., 1996; Paez et al., 2004) . In contrast, autoinhibition of nonreceptor tyrosine kinases and phosphatases, such as JAK2, results from interdomain interactions with activating mutations often arising in interdomain interfaces. For example, mutations in the SH2 and SH3 domain interfaces in BCR-ABL relieve autoinhibition of the kinase domain (Smith et al., 2003) , and activating mutations in the SHP-2 phosphatase seen in Noonan's syndrome and in a subset of juvenile myelomonocytic leukemias disrupt the autoinhibitory SH2 domain/phosphatase domain interface (Tartaglia et al., 2001; Tartaglia et al., 2003) . We propose that the V617F substitution in the pseudokinase domain of JAK2 releases autoinhibitory interdomain interactions, leading to constitutive kinase activation. Structural modeling of the JH1-JH2 domains of JAK2 is consistent with this possibility (see Supplemental to retain the essential features of the protein kinase fold, including the smaller β sheet-rich N-lobe and the larger, mostly helical C-lobe. Val 617 (indicated in red) is expected to lie exposed on the upper surface of the N-lobe at the C-terminal end of strand β4. Note that Val617 lies at the edge of a conserved patch that includes residues of the C-helix and the N-terminal portion of the region corresponding to the activation loop (colored orange). We hypothesize that this residue participates in interdomain interactions that inhibit JAK catalytic activity. The figure was made using the program SETOR (Evans, 1993) . B: Western blot experiments with 293T cells. The upper blots show phosphorylation status of JAK2 in 293T cells overexpressing wild-type JAK2 or the JAK2V617F protein (left panel), or in 293T cells with lower level expression of wild-type JAK2, JAK2V617F, or empty vector (right panel). These blots demonstrate a marked increase in JAK2 autophosphorylation in cells expressing the JAK2V617F mutant. The lower panels show similar levels of expression of JAK2 in the cells transfected with wild-type or mutant JAK2, respectively. C: Expression of increasing amounts of wild-type JAK2 does not influence tyrosine phosphorylation of JAK2V617F, indicating that the wild-type allele does not have dominant negative inhibitory activity. From left to right, 0, 300, 600, and 900 ng of the wild-type JAK2 expression vector was cotransfected with 300 ng of the JAK2V617F expression vector. The upper blot shows no change in JAK2 phosphorylation, while the lower blot shows increasing expression of JAK2. D: Erythropoietin hypersensitivity in Ba/F3-EPOR cells expressing JAK2V617F. 2.5 × 10 5 Ba/F3-EPOR cells stably expressing wild-type JAK2 or JAK2V617F were cultured in triplicate in RPMI/10% FCS containing EPO 1 U/ml, 0.01 U/ml, 0.001 U/ml, or in the absence of EPO for 7 days. Error bars denote the Data, section "Predicted model of the JAK2V617F allele.") (Lin-plained by disease alleles other than JAK2V617F. We did not observe additional JAK2 mutations in PV, nor were mutations dauer et al., 2001). Solution of the JAK2 JH1-JH2 structure will be required to confirm this possibility, and may also provide detected in the activation loop or in the JH2 domain of JAK1, JAK3, or TYK2, respectively (data not shown). High-throughput insight into the selection for the JAK2V617F mutation, as opposed to other activating alleles, in all patients.
sequencing combined with other genome-wide screening methods may eventually identify other mutations. Alternatively, The observation that a single mutant allele is present in a significant proportion of PV, ET, and MMM is also of interest it is possible that patients lacking the JAK2V617F mutation may be false negatives due to sequencing granulocyte DNA in that these are distinct clinical entities. This is similar to the association of a single disease allele, the BCR-ABL gene re-in patients with erythroid (PV) or megakaryocytic (ET) lineage diseases. Mutational analysis of purified hematopoietic pro-arrangement, with a spectrum of hematologic malignancies that includes CML, CML in blast crisis, de novo AML, and B genitors from patients with each of these diseases should resolve this question and may also identify the target cell for cell ALL. The basis for phenotypic pleiotropy in patients with the same disease allele could include host modifiers, differ-transformation. Although nearly all patients had wild-type JAK2 alleles in ences in the hematopoietic progenitor in which the mutation occurs, or as yet unidentified second mutations that contribute DNA derived from buccal swabs, 12 patients (4%) had V617F substitutions. Further study will be required to determine to phenotype. However, there is also significant clinical overlap between the MPD syndromes. For example, patients with ET whether the JAK2V617F allele is a heritable disease allele in families at increased risk for PV and other MPD. Our study may progress to PV, patients with PV who are iron-deficient may present with signs and symptoms of ET, and patients with protocol did not permit for followup with family members for patients who reported family histories of MPD, but ultimately it ET or PV may progress to develop severe myelofibrosis. It will also be of interest to determine whether there are substantive should be possible to determine whether JAKV617F can be transmitted in the germline. Familial predisposition to PV and differences in patterns of global gene expression between MMM, PV, and ET patients, but these genotypic data suggest other MPD has been described, although the genetic basis for predisposition is not known (Kralovics et al., 2003) . Inherited these diseases may be more alike than disparate.
A significant proportion of PV, ET, or MMM patients (26%, 68%, mutant alleles that activate kinases and other signaling intermediates in cancer have been described, including PTPN11 in and 65%, respectively) do not have detectable JAK2V617F mutations in granulocyte DNA. This observation may be ex-Noonan's syndrome associated with juvenile myelomonocytic residing in the United States who had not undergone stem cell transplantaleukemia and RET mutations in multiple endocrine neoplasia tion were eligible for the study. Potential participants e-mailed investigators type II (Mulligan et al., 1993; Tartaglia et al., 2001) . The obserindicating their initial interest, their names, and their mailing addresses. Invation that patients may carry heterozygous JAK2V617F alleles formation packets including a cover letter detailing study goals and in their germline but not develop clinical disease until later in requirements, a consent form, a release of medical records form, a selflife suggests that the JAK2V617F allele may be a less potent administered questionnaire, and a self-addressed, stamped envelope were disease allele than other inherited disease alleles; this has been sent via U.S. mail to potential participants. The self-administered questionobserved with specific RET mutations in multiple endocrine naire consisted of 46 items, including the Medical Outcomes Study Short Form 12 (SF12) (Ware et al., 1996) and the Katz modification of the Charlson neoplasia type II which often do not manifest until later in life comorbidity index (Katz et al., 1996) . Additional constructed questions col- (Gimm et al., 2002) .
lected information regarding diagnosis, symptoms at presentation, and
The identification of JAK2 mutations in MPD is consistent treatment.
with previous genetic and functional data. Loss of heterozy-After signed consent forms and questionnaires were returned to investigosity due to mitotic recombination at chromosome 9p24, the gators and eligibility verified, medical records were requested for abstracgenomic locus of JAK2, has been identified in w30% of pation and biologic sample kits were mailed to participants. In this study detients with PV (Kralovics et al., 2002) , which is similar to the sign, diagnosis relied upon patient self-report. In cases where patients indicated they had two or more diagnoses, first diagnosis was taken as the frequency of JAK2V617F homozygous mutations in PV papatient's diagnosis. If a blood sample did not yield adequate DNA, or if selftients (w25%). TEL/JAK2 fusion genes have been cloned from reported diagnosis was other than PV, ET, or MMM, the patient was expatients with atypical CML and ALL (Lacronique et al., 1997;  cluded from the genetic analysis. In order to verify validity of self-reported Peeters et al., 1997) , and expression of the TEL/JAK2 fusion diagnosis, medical records including pathology samples, laboratory values, protein in a retroviral murine bone marrow transplant model and physician notes were reviewed to confirm if records supported the paresults in a high penetrance and short latency myeloproliferatient's self-reported diagnosis.
tive and lymphoproliferative disease (Schwaller et al., 1998) . Activating EPOR mutations that result in activation of JAK2 and value as a complement to diagnostic tests, such as red blood appended PCR primers for the activation loops of receptor tyrosine kinases were identical to those previously described (Paez et al., 2004) , and addi-cell mass, in delineating PV from secondary erythrocytosis. In tional primers are listed in Supplemental Table S3 . PCR products were puriaddition, comprehensive genotypic analysis should ultimately fied (SPRI, Agencourt Bioscience Corporation), followed by bidirectional seallow for the development of molecularly annotated diagnosquencing and sequence detection on an ABI Prism 3730 DNA Analyzer tic approaches to PV, ET, and MMM, in which there is con- , 2001; Lynch et al., 2004; Paez et al., 2004) . Our data indiwas performed using Mutation Surveyor version 2.28 (SoftGenetics). Candicate that JAK2V617F is a constitutively activated tyrosine kidate mutations were reamplified and sequenced from the original DNA samnase that can also be inhibited with small molecule inhibitors ple for independent verification.
in vitro, and may be a good target for therapeutic intervention in a subset of PV, ET, or MMM. Finally, activation of the JAK-
Genotyping of JAK2V617F allele
STAT pathway has also been reported in a spectrum of solid Genotyping was performed by MALDI-TOF MS analysis. Forward (5#-ACGTTGGATGAGGCATTAGAAAGCCTGTAG-3#) and reverse (5#ACGTTG tumors, and thus genotypic analysis of JAK family members in GATGGCTTTCTCACAAGACATTTGG-3#) PCR primers and the primer solid tumors may also be warranted.
extension probe (5#-ACTCTCGTCTCCACAGA-3#) were designed using SpectroDESIGNER software (Sequenom). Following PCR amplification, un-Experimental procedures incorporated nucleotides were dephosphorylated using shrimp alkaline phosphatase (Amersham). Primer extension was carried out in the presence Harvard myeloproliferative disorders study of dATP, ddCTP, ddGTP, and ddTTP using ThermoSequence polymerase From January 2004 through January 2005, biologic samples and clinical (Amersham) . Primer extension reaction products were loaded onto a data were collected through a protocol that was approved by the Dana-SpectroChip (Sequenom) and analyzed by MALDI-TOF (SpectroREADER, Farber Cancer Institute Institutional Review Board, and all subjects provided Sequenom). SpectroTYPER (Sequenom) was used to analyze mass spectra written informed consent. The study was advertised through the website http://www.mpdinfo.org. All patients 18 years or older with ET, PV, or MMM and determine genotypes based on peak intensities of the predicted primer extension products. A detailed protocol is available at http://www.hapmap. the JH2 domain of JAK2 (Schwede et al., 2003) . The sequence for residues Ser550 to Leu808 of JAK2 was submitted to SwissModel for a first ap-org/downloads/genotyping_protocols.html.
proach mode search using the Protein Data Bank (http://www.pdb.org) deposited structure for Bruton's tyrosine kinase (PDB accession code 1K2P) Measurement of gene copy number by quantitative PCR Quantitative PCR was performed using the Factor VIII locus as a reference as a three-dimensional template (sequence identity 26%) (Mao et al., 2001 ).
An energy-minimized model of the JH2 domain of JAK2 was determined locus as previously described, except that an ABI 7700 sequence detector was used (Wilke et al., 2000) . A probe was designed for JAK2 exon 22 and manually checked for global reasonableness. The location of Val 617 in this model is in a similar conformation to the analogous valine residue in (5#TCCAATTTTAACTCTGTTCTCGTTCTCCACCA3#) using Primer Express software (Applied Biosystems). Priming sequences were JAK2 F (5#-CAC other tyrosine kinase crystal structures that have been solved, e.g., Val256 in CSK (PDB accession code 1BYG) (Lamers et al., 1999) . AGGGATCTGGCAACGA-3#), and JAK2 R (5#-TTGTGGCAAGACTTTGGT TAACC-3#).
Amplification of sample DNA and of male reference DNA was prepared Statistical methods in parallel and amplified on the same run for each sample in triplicate. A
The association between mutational status, either heterozygous, homozysingle copy control was not available, so all samples were compared to gous, or germline, and subject characteristics such as current age, age at male reference DNA with 2 copies of the JAK2 locus. Copy number of the diagnosis, gender, race, comorbidity, physical functioning, prior thrombosis, JAK2 locus per haploid genome for each sample was determined by the self-reported family history, and disease duration was tested by Chi square, ratio of the means of relative copy number of the JAK2 locus and the Factor Fisher's exact, or Wilcoxon rank-sum statistics as appropriate. Only p val-VIII locus in males, and by multiplying this ratio by a factor of 2 in females.
ues less than 0.01 are reported because of multiple testing.
Fluorescence in situ hybridization
Bone marrow fixed cells from patients with verified diagnosis of PV were Supplemental data retrospectively selected from the collection at the Department of Human Supplemental Data for this article can be found at http://www.cancercell. Genetics (Leuven) for FISH. FISH was performed as described (Martinorg/cgi/content/full/7/4/387/DC1/. Subero et al., 2002) . Two probes spanning the JAK2 locus, 197L5 and 725M10, were used (RPCI6 library, available at http://www.chori.org/ BACPAC). These patients were also genotyped for the presence of the Acknowledgments JAK2V617F mutation. Basic Research Scholar Award, and S.F. is supported by grant FR 2113/ fetal calf serum. Transient cotransfection of 293T cells and generation of 1-1 from the Deutsche Forschungsgemeinschaft. We thank the myeloprolifretroviral supernatant were performed as previously described (Schwaller erative disease patients who participated in this study, and Joyce Niblack, et al., 1998) . Ba/F3 cells expressing the murine EPOR (BaF3-EPOR) (D'An-J.D., for support and access to the mpdinfo.org website. We thank Radek drea et al., 1991) were grown in RPMI medium with 10% fetal calf serum Skoda and Tony Green for sharing data prior to publication. We are indebted and 1 unit of EPO per milliliter. Ba/F3-EPOR cells were transduced with to Sarah Cohen, Allison Coburn, Rachel Okabe, Elizabeth McDowell, Dana retroviral supernatant containing either the MSCV-JAK2-Neo or MSCV-Cullen, Gulnar Pothiawala, Nicole Mentens, and Claudia Tenen for assis-JAK2V617F-Neo vectors, respectively, and then selected in G418 (1 mg/ml).
tance with sample processing, to Tarrah Kirkpatrick and Arnold Gonzales To assess for EPO sensitivity, the transduced Ba/F3-EPOR cells were for assistance with the MPD study, to Liuda Ziaugra for assistance with washed three times in phosphate-buffered saline (PBS) and cultured at con-Sequenom genotyping, and to Alexis Bywater for technical and administracentrations of EPO 1 U/ml, 0.01 U/ml, 0.001 U/ml, or without EPO for 7 tive assistance. PCR and sequencing were performed through a contractual days, respectively. The number of viable cells was determined by trypan arrangement with Agencourt Bioscience Corporation. blue exclusion. Leukemia cell lines HEL, K562, RPMI-8402, and MOLT16 were grown in RPMI medium with 10% fetal calf serum without cytokines. For Western blotting, leukemia cell lines were incubated in the presence of JAK inhibitor I (Calbiochem) for 4 hr. For dose response curves, leukemia
Western blotting
Adamson, J.W., Fialkow, P.J., Murphy, S., Prchal, J.F., and Steinmann, L. Cell lines were collected and lysed in lysis buffer (Invitrogen) and separated (1976) . Polycythemia vera: Stem-cell and probable clonal origin of the disby electrophoresis as previously described (Cools et al., 2003) . The followease. N. Engl. J. Med. 295, 913-916. ing antibodies were used for Western blot analysis: anti-phospho-JAK2 (Cell Signaling), anti-JAK2 (polyclonal antibody raised against the JH1 do-Apperley, J.F., Gardembas, M., Melo, J.V., Russell-Jones, R., Bain, B.J., Baxter, E.J., Chase, A., Chessells, J.M., Colombat, M., Dearden, C.E., et al. main of JAK2), antiphosphotyrosine (4G10) (Upstate), anti-phospho-STAT5 (2002) . Response to imatinib mesylate in patients with chronic myeloprolif-(Cell Signaling), anti-STAT5α (Cell Signaling), anti-phospho-ERK1/2 (Cell erative diseases with rearrangements of the platelet-derived growth factor Signaling), peroxidase-conjugated antimouse immunoglobulin (Amersham receptor beta. N. Engl. J. Med. 347, 481-487. Pharmacia Biotech), and peroxidase-conjugated antirabbit immunoglobulin (Amersham Pharmacia Biotech).
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